Company Page

Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines for cancer and rare diseases. The company utilizes proprietary non-viral gene engineering technologies including the piggyBac DNA Modification System and Cas-CLOVER gene editing to develop CAR-T therapies and in vivo gene therapies. Poseida was acquired by Roche in January 2025 for up to $1.5 billion, establishing Roche as a leader in off-the-shelf cell therapy.

Company Founded in 2014

Healthtech & Biotech